Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | HTR6 | P50406 | 2/20 | 0.62 |
| ▸ | MPO | P05164 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.62 |
| ▸ | HTR1B | P28222 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 1/20 | 0.62 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 4/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10577333 | 0.95 | SLC6A4 (0.61) | SLC6A4HTR2ACYP3A4HTR2CHTR6 | |
| SCHEMBL4229484 | 0.89 | HTR2A (0.67) | SLC6A4HTR2ACYP3A4HTR2CHTR6 | |
| SCHEMBL29756457 | 0.89 | HTR2A (0.67) | SLC6A4HTR2ACYP3A4HTR2CHTR6 | |
| SCHEMBL7004146 | 0.88 | HTR2A (0.71) | SLC6A4HTR2ACYP3A4HTR2CHTR6 | |
| SCHEMBL7005718 | 0.88 | HTR2A (0.71) | SLC6A4HTR2ACYP3A4HTR2CHTR6 | |
| SCHEMBL7889427 | 0.86 | HTR2A (0.69) | SLC6A4HTR2ACYP3A4HTR2CHTR6 | |
| SCHEMBL7001306 | 0.86 | HTR2A (0.69) | SLC6A4HTR2ACYP3A4HTR2CHTR6 | |
| SCHEMBL7004071 | 0.86 | HTR2A (0.69) | SLC6A4HTR2ACYP3A4HTR2CHTR6 | |
| SCHEMBL4985934 | 0.84 | HTR2A (0.77) | SLC6A4HTR2ACYP3A4HTR2CHTR6 | |
| SCHEMBL734588 | 0.81 | SLC6A4 (0.63) | SLC6A4HTR2ACYP3A4HTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8691836-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691836-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2014-04-08 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| WO-2011160084-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-1464641-B1 | 4-Phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists | LUNDBECK & CO AS H (DK) | 2008-05-14 | — | — | EP | disclosed |
| US-7223765-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2007-05-29 | — | — | US | disclosed |
| US-7074796-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-11 | — | — | US | disclosed |
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-06 | — | — | US | disclosed |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2003-02-06 | — | — | US | disclosed |
| EP-1246817-A1 | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -TETRAHYDROPYRIDYL DERIVATIVES | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049679-A1 | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -TETRAHYDROPYRIDYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | OPRD1, VDR, GPR4 | SLC6A4 208/4885HTR2A 646/4885CYP3A4 147/4885 |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | SLC6A4 262/4885HTR2A 66/4885CYP3A4 659/4885 |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | OPRD1, DRD3, DRD2 | SLC6A4 679/4885HTR2A 365/4885CYP3A4 771/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | SLC6A4 262/4885HTR2A 66/4885CYP3A4 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.